We are live on ! Find out more
IFRX icon

InflaRx

38 hedge funds and large institutions have $44.1M invested in InflaRx in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,307% more call options, than puts

Call options by funds: $5.58M | Put options by funds: $232K

92% more capital invested

Capital invested by funds: $23M → $44.1M (+$21.1M)

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

9% more funds holding

Funds holding: 3538 (+3)

0.9% more ownership

Funds ownership: 20.09%20.99% (+0.9%)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

Holders
38
Holders Change
+3
Holders Change %
+8.57%
% of All Funds
0.58%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
6
Reduced
10
Closed
8
Calls
$5.58M
Puts
$232K
Net Calls
+$5.35M
Net Calls Change
+$4.33M

IFRX Hedge Fund Activity: Q4 2021 in Review

38 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q4 2021, worth a combined $44.1M — up 92% from $23M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new IFRX positions and 8 closed out — a net gain of 3 holders — while 6 added to existing stakes and 10 trimmed.

The largest buyer was Sofinnova Investments, opening a new position worth an estimated $4.67M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1.55M sold.

  • 38 institutional investors held InflaRx (IFRX) as of Q4 2021, up from 35 in Q3 2021.
  • Funds reported $44.1M of InflaRx stock for Q4 2021, up 92% quarter-over-quarter.
  • 11 funds opened new InflaRx positions in Q4 2021 and 8 closed out, a net change of +3 holders.
  • The largest InflaRx buyer in Q4 2021 was Sofinnova Investments, an estimated $4.67M added.
  • The largest InflaRx seller in Q4 2021 was DAFNA Capital Management, an estimated $1.55M sold.

Based on aggregated 13F filings for Q4 2021.